Skip to main content
. 2021 Jul 12;12:701501. doi: 10.3389/fimmu.2021.701501

Table 2.

Strategies in the design of SARS-CoV-2 vaccines that use RBD of the S glycoprotein.

Developers Vaccine Vaccine platform Phase Design of vaccines using RBD as antigen
Jiangsu Provincial Center for Disease Control and Prevention DelNS1-2019-nCoV-RBD-OPT1 VVr Phase 2 graphic file with name fimmu-12-701501-g019.jpg
West China Hospital + Sichuan University Recombinant (Sf9 cell) PS Phase 2 graphic file with name fimmu-12-701501-g020.jpg
Guangzhou University of Chinese Medicine ND PS ND graphic file with name fimmu-12-701501-g021.jpg
United Biomedical + COVAXX UB-612 PS Phase 1 graphic file with name fimmu-12-701501-g022.jpg
Kentucky BioProcessing KBP-COVID-19 VLP Phase 2 graphic file with name fimmu-12-701501-g023.jpg
AdaptVac (PREVENT-nCoV) ND VLP ND graphic file with name fimmu-12-701501-g024.jpg
Anhui Zhifei Longcom Biopharmaceutical + Institute of Microbiology, Chinese Academy of Sciences RBD-Dimer PS Phase 3 graphic file with name fimmu-12-701501-g025.jpg
Pfizer/BioNTech BNT162b1 RNA Phase 3 graphic file with name fimmu-12-701501-g026.jpg
Cansino Biologics ND – ND graphic file with name fimmu-12-701501-g027.jpg
Sun Yat-sen University ND VLP ND graphic file with name fimmu-12-701501-g028.jpg

Envelope Glycoprotein Signal Sequence from Baculovirus GP67 (GP67 ss), crystallizable fragment of IgG1 (IgG1 Fc), Tobacco mosaic virus (TMV), coat protein of Acinetobacter phage AP205 (AP205), non-toxic mutant of diphtheria toxin (CRM197), SpyCatcher (SC), SpyTag (ST) and secretory signal peptide (SP).